Dr Julia-Dixon Douglas is a Medical Oncologist at the Peter MacCallum Cancer Centre, working within the breast cancer unit.

Julia is also a clinical fellow with Breast Cancer Trials, and is currently undertaking a fellowship project titled: UNRAVEL-TNBC - Uncovering Regulators of Response and Resistance to Immunotherapy in Early-Stage Triple Negative Breast Cancer.

The overall aim is to identify potential biomarkers to individually tailor neoadjuvant immunotherapy in early-stage TNBC. The specific aims to be investigated separately for each cohort are to:

• Investigate baseline characteristics of the tumour-immune micro-environment (TME) associated with pCR and recurrence-free survival.
• Investigate baseline composition of immune cell subsets in peripheral blood associated with pCR and survival.
• Investigate on-treatment dynamics in peripheral immunity and tumour immune microenvironment associated with pCR and recurrence-free survival.
• Correlate features of peripheral immunity with features of the tumour-microenvironment associated with response.